Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Lymphoma 1Lung Neoplasms 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Gynecological Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2capmatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Histologic Type × penpulimab × Clear all
NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
54 enrolled
Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡